The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

Kathrin Schwager, Schwager K, Frank Bootz, Bootz F, Patrick Imesch, Imesch P, Kaspar M, Manuela Kaspar, Eveline Trachsel, Trachsel E, Dario Neri
Human Reproduction · 2011 · vol. 26(9) , pp. 2344–2352 · doi:10.1093/humrep/der195 · PMID:21705369 · W2166047102
Lab / animal OA: bronze CC0 ⤵ 19 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

The F8 antibody specifically targets endometriotic lesions in a mouse model, enabling in vivo imaging and therapeutic delivery of anti-inflammatory IL-10 to reduce lesion size.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Endometriosis is still a highly underdiagnosed disease, and the current medical and surgical treatment of endometriosis is associated with a high recurrence rate. This study investigates the use of derivatives of the human antibody F8, specific to the alternatively spliced extra-domain A of fibronectin (Fn), for the imaging and treatment of endometriosis. METHODS: Immunohistochemistry and immunofluorescence was used to evaluate antigen expression in endometriotic tissue of human endometriosis and of a syngeneic mouse model of the disease. The in vivo targeting performance of a fluorescent derivative of the F8 antibody was assessed by imaging mice with endometriosis using a near-infrared fluorescence imager, 24 h following i.v. injection of the antibody conjugate. Furthermore, the mouse model was used for therapy experiments using two recombinant F8-based immunocytokines [F8-interleukin-10 (IL10) and F8-IL2] or saline for the treatment groups. RESULTS: A very strong vascular expression of splice isoforms of Fn and of tenascin-C was observed in human endometriotic lesions by immunohistochemistry and immunofluorescence techniques. After i.v. administration, a selective accumulation of the F8 antibody in endometriotic lesions could be observed in a syngeneic mouse model. These targeting data were used as a basis for therapy experiments with a pro-inflammatory (F8-IL2) and an anti-inflammatory (F8-IL10) cytokine fusion protein of the F8 antibody. The average lesion size in the F8-IL10 treatment group was clearly reduced compared with the saline control group and with the F8-IL2 group, for which no therapeutic effects were observed. CONCLUSIONS: The F8 antibody targets endometriotic lesions in vivo in a mouse model of endometriosis and may be used for the non-invasive imaging of the disease and for the pharmacodelivery of anti-inflammatory cytokines, such as IL10.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antibodies, Monoclonal Endometriosis Interleukin-10 Alternative Splicing Alternative Splicing Animals Animals Antibodies, Monoclonal Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Humanized Cytokines Cytokines Cytokines Endometriosis Endometriosis Endometriosis Female Female Fibronectins

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (64)

Cited by (21)

Source provenance

europepmc
last seen: 2026-10-23T06:08:06.940705+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:09:10.644269+00:00
License: CC0 · commercial use OK